Combined superior and femoral TLE 121 Tables and Figures Table 1 Baseline characteristics N=264 Demographics - Age (years), median (IQR) 63 (51–71) - Male gender 177 (67.0%) Medical history - Coronary artery disease 87 (33.0%) - Hypertension 65 (24.6%) - Prior cardiac surgery 55 (20.8%) - Diabetes mellitus 49 (18.6%) - Chronic kidney disease (GFR < 45 ml/min) 42 (15.9%) - Peripheral artery disease 5 (1.9%) Antithrombotic agents - Vitamin K antagonist 108 (40.9%) - Antiplatelet agent 73 (27.7%) - NOAC 20 (7.6%) Device type - PM 106 (40.2%) ○ Single-chamber PMa 15 (5.7%) ○ Dual-chamber PM 85 (32.2%) ○ Biventricular PM 6 (2.3%) - ICD 158 (59.8%) ○ Single-chamber ICDb 60 (22.7%) ○ Dual-chamber ICD 45 (17.0%) ○ Biventricular ICD 53 (20.1%) Indications - CIED-related infection 70 (26.5%) ○ Isolated pocket infection/erosion 39 (14.8%) ○ Systemic infection 31 (11.7%) - No CIED-related infection 194 (73.5%) ○ Lead malfunction 169 (64.0%) ○ Other indicationc 25 (9.5%) Dwelling time oldest targeted lead (years), median (IQR) 6.8 (4.0–9.7) Data are presented as number (percentages), unless stated otherwise. CIED cardiac implantable electronic device, ICD implantable cardioverter defibrillator, NOAC non-vitamin K oral anticoagulation, PM pacemaker, TLE transvenous lead extraction a Including 3 VDD pacemakers b Including 2 VDD ICDs c Including 18 upgrade procedures 7
RkJQdWJsaXNoZXIy MTk4NDMw